Human Genome Sciences Company Description
Human Genome Sciences (HGS) knows that the path to good health starts at the molecular level. Using its expertise in human genetics, the firm is working on therapies for infectious and autoimmune diseases and cancer. One of its lead candidates is Albuferon, a long-acting version of protein therapy interferon alpha, that it is developing with Novartis to treat hepatitis C. Monoclonal antibody LymphoStat-B is also in later stages of clinical testing; GlaxoSmithKline is HGS' partner on the drug. With funding from the US government, HGS is developing an antibody that fights anthrax infection, and it has several anticancer antibodies at earlier stages of development.
View the Comprehensive Company Description for Human Genome Sciences
The Company Description provides a historical perspective of Human Genome Sciences's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Human Genome Sciences's evolution in the marketplace.
